达尔西利联合来曲唑对绝经后激素受体阳性乳腺癌的效果

Abstract: Objective To explore the efficacy of dalciclib combined with letrozole in the treatment of postmenopausal HR+ breast cancer patients and its adverse reactions. Methods A total of 60 postmenopausal HR+ breast cancer patients from September 2022 to December 2024 were retrospectively selected and divided into the letrozole group (30 cases were given letrozole) and the combination group (30 cases were given dalciclib combined with letrozole) according to the medication regimens. The therapeutic effects, serum factors, tumor markers, maximum diameter of cancer lesions, adverse reactions and quality of life of the two groups were compared. Results The rate of the combined group was higher than that of the letrozole group (P＜0.05). The levels of tumor necrosis factor (TNF) -α in the combined group were lower than those in the letrozole group (P＜0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), and carbohydrate antigen 125 (CA125) in the combined group were lower than those in the letrozole group (P＜0.05). The maximum diameter of cancer lesions in the combined group was lower than that in the letrozole group (P＜0.05). There was no difference in the adverse reaction rate between the two groups (P＞0.05). The score of the functional assessment of cancer therapy-breast (FACT-B) in the combined group was higher than that in the letrozole group (P＜0.05). Conclusion The therapeutic effect of dalciclib combined with letrozole in the treatment of postmenopausal HR+ breast cancer is relatively good. It can effectively reduce the levels of serum factors and tumor markers, shrink the cancer focus, improve the quality of life of patients, and the safety is comparable.